Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-14T11:15:54.723Z Has data issue: false hasContentIssue false
  • English
  • Français

Which dose of haloperidol?

Published online by Cambridge University Press:  02 January 2018

Trudi Hilton,
David Taylor and
Kathryn Abel
Trudi Hilton
Affiliation:
Maudsley Hospital, London SE5 8AZ
David Taylor*
Affiliation:
Maudsley Hospital, London SE5 8AZ
Kathryn Abel
Affiliation:
Maudsley Hospital, London SE5 8AZ
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Although haloperidol (HAL) has been available as an antipsychotic for over 30 years, controversy still surrounds the appropriate dose in the treatment of psychosis and in particular, schizophrenia. In practice, high dose HAL (greater than 20 mg/day) continues to be prescribed, despite good reason for not doing so: the incidence of extrapyramidal side-effects (EPSE) is known to be dose-related; and compliance with treatment may be adversely affected by side-effects, especially akathisia and Parkinsonism.

Information

Type
Drug Information Quarterly
Information
Psychiatric Bulletin , Volume 20 , Issue 6 , June 1996, pp. 359 - 362
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1996

References

Baldessarini, R. T., Cohen, B. M., Teicher, M. H., et al (1988) Significance of neuroleptic dose and plasma level in pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79–91.Google Scholar
Bazire, S. (1995) The Psychotropic Drug Directory. Salisbury: Quay Books.Google Scholar
British Medical Association & The Royal Pharmaceutical Society (1993) British National Formulary (BNF), No. 26. London: BMA & The Pharmaceutical Press.Google Scholar
Dewan, M. J. & Koss, M. (1995) The clinical impact of reported variance in potency of antipsychotics. Acta Psychiatrica Scandinavica, 91, 229–232.Google Scholar
Farde, L., Nordstrom, A.-L., Wiesel, F.-A., et al (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry, 49, 538–544.CrossRefGoogle ScholarPubMed
Harvey, P. D., Davidson, M., Powchik, P., et al (1991) Time course and clinical predictors of treatment response in schizophrenia. Schizophrenia Research, 5, 161–166.Google Scholar
Leblanc, G., Cormier, H., Gagne, M.-A., et al (1994) Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Canadian Journal of Psychiatry, 39, 223–229.CrossRefGoogle ScholarPubMed
McEvoy, J. P., Hogarty, G. E. & Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry, 48, 739–745.Google Scholar
Midha, K. K., Hubbard, J. W., Marder, S. R., et al (1994) Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. Journal of Psychiatry and Neuroscience, 19, 254–264.Google ScholarPubMed
Nyberg, S., Farde, L., Halldin, C., et al (1995) D2 dopamine receptor occupancy during low-dose treatment with HAL decanoate. American Journal of Psychiatry, 152, 173–178.Google Scholar
Rifkin, A., Doddi, S., Karajgi, B., et al (1991) Dosage of HAL for schizophrenia. Archives of General Psychiatry, 48, 166–170.Google Scholar
Stone, C., Garver, D., Griffith, J., et al (1995) Further evidence of a dose-response threshold for HAL in psychosis. American Journal of Psychiatry, 152, 1210–1212.Google Scholar
Tandon, R., Mann, N. A., Eisner, W. H., et al (1990) Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Research, 31, 235–241.Google Scholar
The Royal Pharmaceutical Society of Great Britain (1993) Martindale – The Extra Pharmacopoeia (30th edn). London: The Pharmaceutical Press.Google Scholar
Van Putten, T., Marder, S. R. & Mintz, J. (1990) A controlled dose comparison of HAL in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754–758.CrossRefGoogle Scholar
Van Putten, T., Marshall, B. D., Liberman, R., et al (1993) Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacology Bulletin, 29, 315–320.Google ScholarPubMed
Vuckovic, A., Cohen, B., Keck, P., et al (1990) Neuroleptic dosage regimens in psychotic inpatients: A retrospective comparison. Journal of Clinical Psychiatry, 51, 107–109.Google Scholar
Volavka, J., Cooper, T. B., Meisner, M., et al (1990) Dosage effect in psychopharmacology: issues and empirical studies. Psychopharmacology Bulletin, 26, 13–17.Google Scholar
Volavka, J., Cooper, T., Jczobor, P., et al (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry, 52, 837–845.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.